Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.08 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)2.68M
Market Cap
$989.66M
Enterprise Value$1.46B
Total Cash (Recent Filing)$346.19M
Total Debt (Recent Filing)$604.78M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Jul 30, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding128,694,500
10 Day Avg. Volume4,449,120
30 Day Avg. Volume2,684,264
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-15.65K
Forecast
1Y Price Target
$12.50Price Target Upside56.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Clinical Revenue GrowthClinical revenue showed growth, indicating a positive contribution to the overall revenue.
Underestimated ValueShares are undervalued and not reflective of the value of the entity, trading at 1.4 times NTM revenue, a 13-year low.
Valuation SupportValuation provides downside support on sharp pullback, with NGS pipeline execution being key to recovery.
Bears Say
Competitive Market ChallengesThe competitive landscape in the oncology diagnostics market is increasing, making growth expectations unlikely to materialize.
Management Turnover RiskRecent management changes increase the risk of further senior management turnover.
Overly Optimistic GuidanceThe revenue growth forecast for 2025 appears overly optimistic and is likely to be reduced.
---
Ownership Overview
1.04% Insiders
35.30% Mutual Funds
0.13% Other Institutional Investors
38.14% Public Companies and
Individual Investors
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $6.08 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $989.66M.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Jul 30, 2025 which is in 82 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Apr 29, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.013.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.03.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,694,500 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went down -34.002%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
---
NeoGenomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (56.25% Upside)
$12.50 (56.25% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 345.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $111.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.41%
12-Months-Change
Fundamentals
Return on Equity
-8.57%
Trailing 12-Months
Asset Growth
-2.37%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a leading cancer diagnostics and pharmaceutical services company providing comprehensive testing services to hospitals, pathologists, oncologists, and other healthcare providers across the United States. The company specializes in cancer genetics testing and information services, offering a broad menu of diagnostic tests that include cytogenetics, flow cytometry, FISH, IHC, and molecular testing. It aims to improve patient care through high-quality genetic and molecular testing services, enabling a better understanding of cancer and patient outcomes.
---
NEO Company Deck
---
NEO Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with significant growth in revenue and EBITDA, expansion through acquisitions, and strong performance in clinical testing volumes and NGS revenue. However, there were challenges in the non-clinical sector, particularly in pharma and biotech spending. Despite these challenges, the company's strategic initiatives and market positioning in oncology provide a robust outlook.Read More>---
NEO Stock 12 Month Forecast
Average Price Target
$12.50
▲(56.25% Upside)
Technical Analysis
---